{
  "pmcid": "1357739",
  "sha256": "dcd4da24f1a95c83aea4a967109625efdffbe6de2b97924e6d461da0ca72db51",
  "timestamp_utc": "2025-11-09T22:31:52.768002+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.225937219730941,
    "reading_ease": 26.718427503736933,
    "word_count": 223
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intraoperative Lymphatic Mapping and Sentinel Node Biopsy in Early-Stage Melanoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients with primary cutaneous melanoma (≥1 mm with Clark level ≥III, or any thickness with Clark level ≥IV) were randomly assigned in a 4:6 ratio"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with primary cutaneous melanoma (≥1 mm with Clark level ≥III, or any thickness with Clark level ≥IV)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned in a 4:6 ratio to wide excision (WE) plus observation (WEO) with delayed complete lymphadenectomy (CLND) for nodal recurrence, or to WE plus LM/SNB with immediate CLND for sentinel node (SN) metastasis"
      },
      "Objective": {
        "score": 1,
        "evidence": "This international multicenter phase III trial aimed to evaluate the accuracy, use, and morbidity of intraoperative lymphatic mapping and sentinel node biopsy (LM/SNB) for staging regional nodal basins in early-stage melanoma."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the accuracy of LM/SNB, measured by SN identification rates and nodal metastases incidence, over a recruitment period ending March 31, 2002"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was conducted after each center achieved 85% accuracy in SN identification during a 30-case learning phase."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "over a recruitment period ending March 31, 2002, with 2001 patients enrolled"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "SN identification rate was 95.3% overall."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "SN identification rate was 95.3% overall. False-negative LM/SNB rates decreased with increasing case volume: 10.3% for the first 25 cases versus 5.2% after 25 cases."
      },
      "Harms": {
        "score": 1,
        "evidence": "Complication rates were 10.1% for LM/SNB, increasing to 37.2% with CLND."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}